Výsledky vyhledávání

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Autor: Rina Mehta, Leorah Freeman, Arianna Kee, Marc Tian

Publikováno v: Drugs-Real World Outcomes

Background Real-world studies of disease-modifying therapies (DMTs) in multiple sclerosis (MS) have reported suboptimal adherence. Objective We aimed to describe treatment patterns, relapses, healthcare resource utilization, and costs in MS patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03bdfc01ed05da100fd3ae74a9dfa641
http://europepmc.org/articles/PMC8605953

Zobrazit plný text záznamu

A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany

Autor: Hartmut Link, Stephen F. Thompson, Marc Tian, Jennifer S. Haas, Dominic Meise, Christopher Maas, Stamen Dimitrov

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 30(11)

We assessed the occurrence of neutropenia and febrile neutropenia (FN) and the associated healthcare resource in cancer patients receiving myelosuppressive chemotherapy in combination with pegfilgrastim versus lipegfilgrastim.This is a retrospective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::224837eec8c433155c0d81c748d754db
https://pubmed.ncbi.nlm.nih.gov/36076105

Zobrazit plný text záznamu

Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis

Autor: Ila Sruti, Machaon Bonafede, Corey Pelletier, Neil Goldfarb, Marc Tian, Gilwan Kim, Rina Mehta

Publikováno v: PharmacoEconomics Open

Objectives The aim of this study was to examine the indirect burden of employed multiple sclerosis (MS) patients initiating disease-modifying therapies (DMTs) in the US. Methods DMT-treated MS patients (DMT users) and direct-matched controls without

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2424c0753b90bcf61b482174f8f87270
https://doi.org/10.1007/s41669-020-00233-8

Zobrazit plný text záznamu

Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis

Autor: Corey Pelletier, Ibrahim Khilfeh, Marc Tian, Brian Ung, Chuka Udeze, David L. Kaplan

Publikováno v: ClinicoEconomics and Outcomes Research. 12:369-377

Purpose Compare treatment switching rates and costs among biologic-naive psoriasis patients initiating apremilast or biologics. Methods This retrospective claims analysis used IBM MarketScan Commercial and Medicare Supplemental databases to identify

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c4194de856b9b6b6219dbeea821f36bc
https://doi.org/10.2147/ceor.s251775

Zobrazit plný text záznamu

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Autor: Rina Mehta, Corey Pelletier, Virginia Noxon, James Bowen, Barbara H. Johnson, Marc Tian, Machaon Bonafede

Publikováno v: Advances in Therapy

Objective Disease-modifying therapies (DMTs) can reduce multiple sclerosis (MS) relapse rates; however, effectiveness of treatments may vary. It is important to understand real-world treatment patterns in the context of MS relapses. We describe MS re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21fea90cde44e5f75d15d510be37ed48
https://doi.org/10.1007/s12325-020-01367-1

Zobrazit plný text záznamu

Abstract P2-08-09: Treatment patterns and costs of metastatic triple negative breast cancer (mTNBC) in US women: A retrospective cohort study of first-line chemotherapy

Autor: Ronda Copher, Marc Tian, Ashley Tabah, Sarah S. Mougalian, David Huggar

Publikováno v: Cancer Research. 80:P2-08

Background: TNBC disproportionally affects younger women and is the leading cause of cancer-related deaths in women under 40. Treatment burden likely has a greater impact in younger women given employment and/or parental status. Little is known about

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ddeb67f7030a90c15441571e58095271
https://doi.org/10.1158/1538-7445.sabcs19-p2-08-09

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání